Abstract
Abstract Hypopituitarism is the consequence of diseases or interventions resulting in deficiency of pituitary hormones. Pituitary hormone replacement is one of the most frequent clinical interventions in pituitary disease, yet is rarely been the subject of rigorous scientific evaluation. With the exception of growth hormone, anterior pituitary hormones are replaced with target hormones (sex steroids, cortisol, and thyroxine), in preference to pituitary trophic hormones, as the former have longer half-lives allowing for oral administration. The precise reason for increased morbidity and mortality associated with hypopituitarism is unclear, but underlines the importance of replacing hormones close to physiological patterns. In an era of ‘evidence-based’ medicine, recommendations are frequently based on clinical experience, consensus guidelines, and retrospective reviews rather than on randomized trials. Within these limitations, this chapter will attempt to give a balanced view on current best practice for replacement therapy in adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), and gonadotrophin deficiency.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
